-+ 0.00%
-+ 0.00%
-+ 0.00%

Roth Capital Reiterates Buy on Insmed, Maintains $212 Price Target

Benzinga·04/17/2026 17:46:45
Listen to the news
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $212 price target.